Catalent plans to close its Gosselies, Belgium cell‑therapy facility, citing changing market dynamics and customer needs. The move raises questions about capacity and access for cell therapy developers in Europe as CDMOs recalibrate footprints. Separately, industry commentary emphasizes that raw‑material selection and lot variability remain critical bottlenecks in cell therapy manufacturing—affecting cytokines, sera, and ancillary components that drive product consistency. Experts warn that variability in inputs can alter transduction rates, cell phenotype and downstream potency attributes, underscoring why manufacturing strategy and supply‑chain alignment are now central to clinical and commercial readiness.